

1. Record Nr.	UNISA996392336503316
Titolo	Several votes of the Commons assembled in Parliament [[electronic resource] ] : against certain papers delivered in to them in the name of all the freeborn people of England. Ordered by the Commons assembled in Parliament that these votes be forthwith printed and published. H. Elsynge, Cler. Parl. D. Com
Pubbl/distr/stampa	London, : Printed for Edward Husband, Printer to the Honorable House of Commons, Nov. 25. 1647
Descrizione fisica	8 p
Soggetti	Seditious libel - England Great Britain Politics and government 1642-1649 Early works to 1800
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Reproduction of the original in the British Library.
Sommario/riassunto	eebo-0018

2. Record Nr.	UNINA9910785115503321
Autore	Jogdand S. N
Titolo	Biopharmaceuticals [[electronic resource] /] / S.N. Jogdand
Pubbl/distr/stampa	Mumbai [India], : Himalaya Pub. House, 2006
ISBN	1-282-80173-2 9786612801730 1-4416-6139-5 93-5043-529-2 600-00-2715-X
Edizione	[1st ed.]
Descrizione fisica	1 online resource (283 p.)
Disciplina	615/.7
Soggetti	Biopharmaceutics
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	COVER; CONTENTS; INTRODUCTION; MARKET FOR BIOPHARMACEUTICALS; BIOPHARMACEUTICAL INDUSTRY; BIOPHARMACEUTICAL SECTOR IN INDIA; DRUG DISCOVERY AND DRUG DESIGNING; PHARMACOKINETICS; CLINICAL TRIALS; REGULATORY; THERAPEUTIC PROTEINS; BLOOD PRODUCTS; MONOCLONAL ANTIBODIES; HORMONE THERAPY; VACCINE PRODUCTION-NEW DEVELOPMENTS; TRANSGENIC PRODUCTION OF BIOPHARMACEUTICALS; HUMAN GENE THERAPY; ANTISENSE TECHNOLOGY (DNA MEDICINES)
Sommario/riassunto	Biopharmaceuticals are complex macromolecules created through the genetic manipulation of living organisms using gene cloning, recombinant DNA(gene splicing), or fusion technologies. Although small molecule drugs remain the standard treatment for disease, new strategies based on the engineering of proteins, genes and cell as therapeutic agents will revolutionize medicine in the coming decades. More than 20 percent of new medicines launched in 2003 were produced using biotechnology, nearly 80 percent of those under development either use use of biotechnology or are derived from it. The biopharm